Johannes F. E. Mann
#159,183
Most Influential Person Now
Johannes F. E. Mann's AcademicInfluence.com Rankings
Johannes F. E. Mannengineering Degrees
Engineering
#6783
World Rank
#8125
Historical Rank
Biomedical Engineering
#623
World Rank
#633
Historical Rank
Johannes F. E. Mannphilosophy Degrees
Philosophy
#9120
World Rank
#12629
Historical Rank
Logic
#6112
World Rank
#7595
Historical Rank
Download Badge
Engineering Philosophy
Johannes F. E. Mann's Degrees
- Doctorate Medicine Harvard University
Why Is Johannes F. E. Mann Influential?
(Suggest an Edit or Addition)Johannes F. E. Mann's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016) (2621)
- Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. (2005) (2435)
- Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. (2001) (1938)
- Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency (1996) (1606)
- Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention (2013) (1509)
- Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial (2008) (1488)
- Dapagliflozin in Patients with Chronic Kidney Disease. (2020) (1417)
- Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. (2011) (841)
- Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. (1996) (538)
- Urinary sodium and potassium excretion and risk of cardiovascular events. (2011) (538)
- Liraglutide and Renal Outcomes in Type 2 Diabetes (2017) (495)
- Avosentan for overt diabetic nephropathy. (2010) (423)
- Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. (2005) (374)
- Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. (2002) (365)
- Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease (2008) (337)
- Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study) (2004) (285)
- The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis (2005) (262)
- Changes in albuminuria predict mortality and morbidity in patients with vascular disease. (2011) (247)
- Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. (2000) (236)
- Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. (2013) (200)
- Safety of the combination of valsartan and benazepril in patients with chronic renal disease (2000) (193)
- Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. (2002) (180)
- Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. (2015) (178)
- Plasma angiotensin II: dipsogenic levels and angiotensin-generating capacity of renin. (1980) (173)
- Lowering of hypertension by central saralasin in the absence of plasma renin (1977) (173)
- Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the heart outcomes prevention evaluation study (2000) (165)
- Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. (2000) (157)
- Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONT (2010) (156)
- The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. (1996) (155)
- RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection (2008) (146)
- Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics (2004) (135)
- Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies (2011) (135)
- Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. (2003) (135)
- ACE inhibitors versus AT(1) receptor antagonists in patients with chronic renal disease. (2002) (133)
- Early interstitial changes in hypertension-induced renal injury. (1993) (131)
- Effect of Telmisartan on Renal Outcomes (2009) (127)
- Renal function and outcomes in acute coronary syndrome: impact of clopidogrel (2007) (125)
- Effects of central and peripheral angiotensin blockade in hypertensive rats. (1978) (122)
- The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. (2014) (122)
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients (2015) (120)
- Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. (2013) (118)
- Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. (2004) (109)
- Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. (2000) (107)
- Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. (2021) (104)
- The COOPERATE trial: a letter of concern (2008) (101)
- Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. (2011) (98)
- Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. (2007) (93)
- Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. (2007) (91)
- Risk Prediction for Early CKD in Type 2 Diabetes. (2015) (90)
- Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. (2004) (90)
- Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. (2007) (89)
- Multicystic transformation of kidneys in chronic renal failure. (1984) (88)
- Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. (2015) (88)
- Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. (2003) (84)
- What are the short-term and long-term consequences of anaemia in CRF patients? (1999) (83)
- Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. (1997) (82)
- Plasma angiotensin II concentrations and experimentally induced thirst. (1981) (81)
- Albuminuria and decline in cognitive function: The ONTARGET/TRANSCEND studies. (2011) (79)
- Cardiovascular risk in patients with mild renal insufficiency. (2003) (79)
- Effective CKD care in European countries: challenges and opportunities for health policy. (2015) (78)
- Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial (2010) (78)
- Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial (2013) (76)
- Chronic diabetic nephropathy: role of inducible nitric oxide synthase (2002) (76)
- Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. (2016) (74)
- Sodium intake and renal outcomes: a systematic review. (2014) (69)
- Angiotensin formation in the isolated rat hindlimb. (1989) (69)
- Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease (2018) (67)
- Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. (2020) (65)
- Angiotensin-Converting Enzyme Inhibitors and Kidney Protection: The AIPRI Trial (1999) (62)
- Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial (2020) (62)
- Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. (2018) (61)
- Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. (1997) (60)
- How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? (2004) (59)
- Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease. (2020) (58)
- Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. (2017) (57)
- Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019) (56)
- Natriuresis-pressure relationship in polycystic kidney disease. (1990) (56)
- Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. (2017) (56)
- Central Actions and Brain Receptor Binding of Angiotensin II: Influence of Sodium Intake (1980) (55)
- Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk (2011) (54)
- Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. (2020) (53)
- LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes (2014) (53)
- Effects of an orally active converting-enzyme inhibitor, SQ 14225, on pressor responses to angiotensin administered into the brain ventricles of spontaneously hypertensive rats. (1979) (49)
- A highly selective cardiorenal serotonergic 5-HT3-mediated reflex in rats. (1993) (49)
- Use of angiotensin-converting enzyme inhibitors for the preservation of kidney function. A retrospective study. (1990) (48)
- Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial (2014) (48)
- Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. (2015) (46)
- Angiotensin II facilitates sympathetic transmission in rat hind limb circulation. (1993) (44)
- Mechanisms by which endothelin 1 induces pulmonary vasoconstriction in the rabbit. (1991) (43)
- Hyperparathyroidism and abnormal calcitriol metabolism in the spontaneously hypertensive rat. (1989) (43)
- Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. (2016) (42)
- Brain receptor binding and central actions of angiotensin analogs in rats. (1981) (41)
- The spectrum of renal involvement in epidermolysis bullosa dystrophica hereditaria: report of two cases. (1988) (41)
- Thirst and the renin-angiotensin system. (1987) (41)
- Effects of parathyroidectomy on blood pressure in spontaneously hypertensive rats. (1987) (40)
- Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. (2005) (40)
- Ibuprofen as an over-the-counter drug: is there a risk for renal injury? (1993) (40)
- Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? (2004) (39)
- The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial (2014) (38)
- Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. (1999) (37)
- Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. (2019) (37)
- Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. (2015) (37)
- Nerve-mediated antidiuresis and antinatriuresis after air-jet stress is modulated by angiotensin II. (1996) (35)
- Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation? (2012) (35)
- Hypertension and cardiovascular effects--long-term safety and potential long-term benefits of r-HuEPO. (1995) (35)
- International consensus definitions of clinical trial outcomes for kidney failure: 2020. (2020) (34)
- Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. (2006) (34)
- A Gene Variant in CERS2 Is Associated with Rate of Increase in Albuminuria in Patients with Diabetes from ONTARGET and TRANSCEND (2014) (34)
- Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate. (2001) (34)
- Na+/H+ exchange in human lymphocytes and platelets in chronic and subacute metabolic acidosis. (1993) (34)
- Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. (2005) (33)
- Impaired cardiovascular reflexes precede deoxycorticosterone acetate-salt hypertension. (1994) (33)
- Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies (2003) (32)
- Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial (2020) (32)
- Vascular effects of parathyroid hormone (PTH). (1982) (31)
- Pulmonary serotonin 5-HT3-sensitive afferent fibers modulate renal sympathetic nerve activity in rats. (1997) (31)
- Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study. (2005) (30)
- Reduced chronotropic responsiveness of the heart in experimental uremia. (1986) (29)
- Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. (2020) (29)
- Expression of angiotensin-converting enzyme in renovascular hypertensive rat kidney. (1995) (29)
- Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. (1996) (28)
- Prevalence and long-term outcome of glomerulonephritis in renal allografts. (1993) (28)
- Renal angioplasty for lowering blood pressure. (2000) (28)
- Epicardial bradykinin B2 receptors elicit a sympathoexcitatory reflex in rats. (1996) (27)
- Economic evaluation of benazepril in chronic renal insufficiency. (1997) (26)
- C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. (2010) (26)
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021) (26)
- Haemodynamic effects of intact digoxin antibody and its Fab fragments in experimental hypertension. (1987) (26)
- Effects of human renin in the vasculature of rats transgenic for human angiotensinogen. (1995) (25)
- Modulation of sympathetic vascular tone by prostaglandins in corticosterone-induced hypertension in rats. (1979) (25)
- Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. (2016) (25)
- Renoprotective effects of renin-angiotensin-system inhibitors (2006) (23)
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. (2020) (23)
- Cardiovascular Risk in Patients with Early Renal Insufficiency (2002) (23)
- Angiotensinogen is cleaved to angiotensin in isolated rat blood vessels. (1993) (22)
- Chronic renal transplantation: a model for the hyperhomocysteinemia of renal insufficiency. (2001) (21)
- Rationale and study design of the prospective, longitudinal, observational cohort study “rISk strAtification in end-stage renal disease” (ISAR) study (2016) (21)
- Rotational syndrome after central injection of C-terminal 7-peptide of cholecystokinin (1980) (21)
- Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial (2021) (19)
- One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis (2017) (19)
- PRESERVATION OF KIDNEY FUNCTION BY USE OF CONVERTING-ENZYME INHIBITORS FOR CONTROL OF HYPERTENSION (1987) (19)
- Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial (2018) (19)
- Lead and the kidney. (1988) (19)
- Progression of renal disease--can we forget about inhibition of the renin-angiotensin system? (2006) (19)
- Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. (2011) (18)
- LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial (2016) (18)
- Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. (2013) (18)
- LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations (2015) (18)
- Comparison of 24-hour and Office Pulse Wave Velocity for Prediction of Mortality in Hemodialysis Patients (2019) (17)
- Endothelin antagonism for patients with chronic kidney disease: still a hope for the future. (2014) (17)
- Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. (2017) (17)
- Blood HER2 and Uromodulin as Causal Mediators of CKD. (2018) (17)
- Clinical evaluation of patients with hypertension and exercise-induced renal dysfunction. (1987) (16)
- Human angiotensin II receptors are regulated by angiotensin II. (1988) (16)
- Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial (2017) (15)
- Dietary Sodium and Cardiovascular Disease Risk. (2016) (14)
- Hypertension in diabetes mellitus. (1988) (13)
- A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. (2019) (13)
- Atherosclerotic renal artery stenosis in 2001--are we less confused than before? (2001) (12)
- Effect of valsartan on renal function in patients with hypertension and stable renal insufficiency (1999) (12)
- Cardiac Findings in Experimental Uremia1 (1986) (11)
- Mortality in dialysis patients with cinacalcet use: A large observational registry study. (2017) (11)
- Research needs in the area of device-related treatments for hypertension. (2013) (11)
- CONTRIBUTION OF THE SYMPATHETIC NERVOUS SYSTEM TO THE CENTRALLY‐INDUCED PRESSOR ACTION OF ANGIOTENSIN II IN RATS (1982) (10)
- Vascular production and regulation of angiotensin. (1991) (10)
- A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study (2013) (10)
- Light-chain-induced renal tubular acidosis: effect of sodium bicarbonate on sodium-proton exchange. (1995) (10)
- Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs? (2015) (10)
- Morphological reaction patterns in experimental cardiac hypertrophy--a quantitative stereological study. (1986) (10)
- Nomenclature in nephrology: preserving ‘renal’ and ‘nephro' in the glossary of kidney health and disease (2021) (9)
- Cardiac function in experimental uremia. (1983) (9)
- Salt and the action of calcium antagonists. (1988) (9)
- Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists. (2021) (9)
- Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study (2017) (9)
- Is therapy of people with chronic kidney disease ONTARGET? (2010) (8)
- The acute renal effects of angiotensin II receptor blockers. (1998) (8)
- Effects of combined renovascular hypertension and diabetes mellitus on myocardial cells, non-vascular interstitium and capillaries: a stereological study on rat hearts (2005) (8)
- Looking for people at high cardiovascular risk? Look at serum-creatinine. (2003) (8)
- Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials (2020) (8)
- Pathogenesis of hypertension in glomerular disease. (1989) (8)
- The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations? (2008) (8)
- Brain Angiotensin II Receptors: Possible Physiological Implications (1982) (8)
- What's new in hypertension? (2006) (8)
- Vascular angiotensin and the sympathetic nervous system: do they interact? (1994) (8)
- Should the results of the HOPE study affect nephrological practice? For the HOPE investigators. (2000) (8)
- Specific binding of angiotensin II and atrial natriuretic factor in non-nephropathic type I diabetes mellitus. (1989) (8)
- Synergistic effects of diabetes mellitus and renovascular hypertension on the rat heart - stereological investigations on papillary muscles (2004) (8)
- Does lead play a role in the development of renal insufficiency? (1988) (7)
- Adrenergic responsiveness in experimental uremia. (1984) (7)
- Vascular conversion of angiotensin I in stroke-prone spontaneously hypertensive and Wistar—Kyoto rats (1993) (7)
- Role of hypertension in diabetic nephropathy. (1989) (7)
- NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL (2018) (7)
- Valsartan and the kidney: present and future. (1999) (6)
- Role of the Brain Renin-Angiotensin System in Central Mechanisms of Blood Pressure Control (1981) (6)
- Hypertension in diabetes mellitus. (1988) (6)
- Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial (2020) (6)
- Vasoconstriction and increased blood pressure in the development of accelerated vascular disease (2004) (6)
- D37 Comparison of the angiotensin II antagonist valsartan with the β-blocker atenolol in patients with severe essential hypertension (1997) (6)
- Dual renin–angiotensin system blockade and outcome benefits in hypertension: a narrative review (2015) (6)
- Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. (2020) (6)
- 125I-Angiotensin II binding to human blood cells. (1985) (6)
- Influence of parathyroidectomy on blood pressure and vascular reactivity in spontaneously hypertensive rats. (1989) (5)
- Vascular renin in the guinea pig. Suppression by the renin inhibitor remikiren. (1994) (5)
- Parathormone and blood pressure in the spontaneously hypertensive rat. (1984) (5)
- Effect of antihypertensive therapy on the progression of non-diabetic renal disease. (1992) (5)
- What's new in hypertension 2008? (2008) (5)
- The effects of beta-adrenoreceptor blockers on blood pressure responses to central angiotensin II (1981) (4)
- FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) (4)
- Specific angiotensin binding to human blood cells. (1983) (4)
- Effects of WY 47987 (atrial natriuretic factor 102-126) in patients with renal insufficiency: a placebo-controlled, randomised study. (1989) (4)
- Influence of dietary factors on the renal renin-angiotensin system. (1992) (4)
- Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study (2019) (4)
- Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study) (2015) (4)
- Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". (2019) (4)
- Renin-dependent water intake in hypovolemia (1988) (4)
- Cardiac findings in experimental uremia. (1986) (4)
- The diagnosis of renovascular hypertension: state of the art 1995. (1995) (4)
- Chronische Nierenerkrankungen und kardiovaskuläres System (2008) (4)
- FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) (4)
- WHAT ARE THE SHORT-TERM AND LONG-TERM CONSEQUENCES OF DIABETIC NEPHROPATHY? (1999) (4)
- Influence of hypertension on serum concentration of type IV collagen antigens in streptozotocin-diabetic and non-diabetic rats (1987) (4)
- What's new in hypertension 2010? (2011) (4)
- Tissue renin: focus on vascular angiotensin formation. (1993) (3)
- Angiotensin Dependent Thirst Following Polyethyleneglycol Treatment in the Rat (1986) (3)
- Adding lisinopril to losartan increased hyperkalemia and acute kidney injury in type 2 diabetes and proteinuria (2014) (3)
- How does hemodiafiltration improve survival? (2013) (3)
- Cardiovascular Mortality Can Be Predicted by Heart Rate Turbulence in Hemodialysis Patients (2020) (3)
- [Calcium antagonists in chronic renal failure. Undesirable effects on glomerular hemodynamics?]. (1988) (3)
- FO012NORMALIZATION OF SERUM BICARBONATE WITH SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) IN THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY (2015) (3)
- Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk (2021) (3)
- AIPRI : Angiotensin-converting-enzyme inhibition in progressive renal insufficiency (1996) (3)
- Mechanisms of the antihypertensive action of captopril. (1984) (3)
- Rational drug treatment of the hypertensive diabetic with nephropathy. (1988) (3)
- New Trial Data on Prevention: Potassium and CV Risk in Hope (2003) (3)
- Effects of parathyroidectomy on blood pressure development in eucalcaemic, spontaneously hypertensive rats. (1983) (2)
- [The renin-angiotensin system in diabetic patients]. (1988) (2)
- P2518Arrythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events (2018) (2)
- Effects of beta-adrenergic blocking agents on peripheral vascular resistance. (1978) (2)
- SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) (2)
- New classes of antihypertensive drugs and new findings with established agents. (1992) (2)
- [Antihypertensive therapy and progression of renal failure]. (1987) (2)
- Clinic versus home blood-pressure measurements as a predictor of outcomes in chronic kidney disease (2006) (2)
- Ace inhibition in chronic renal failure: a step forward. (1996) (2)
- Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. (2020) (2)
- What's new in hypertension 2009? (2010) (2)
- Liraglutide and Renal Outcomes in Type 2 Diabetes. (2017) (2)
- Abstract 15035: Liraglutide Reduces Major Cardiovascular Events in Patients With Chronic Kidney Disease: Results From the Leader Trial (2017) (2)
- Different antagonist potency of saralasin in acute and chronic angiotensin-dependent hypertension. (1983) (1)
- Altered beta-receptor responsiveness in uraemic rats. (1983) (1)
- Reaction patterns of the myocardial interstitium in different models of cardiac hypertrophy--stereological investigations. (1989) (1)
- Morphogenesis of hypertensive vascular lesions. (1982) (1)
- FP007EFFICIENCY OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) INCREASES WITH SEVERITY OF HYPERKALAEMIA: SUBGROUP ANALYSIS OF PATIENTS STRATIFIED BY BASELINE POTASSIUM IN THE PHASE 3 HARMONIZE STUDY (2015) (1)
- EFFECT OF SODIUM ZIRCONIUM CYCLOSILICATE (ZS-9) ON URINARY POTASSIUM AND SODIUM: AN ANALYSIS OF THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HARMONIZE STUDY (2015) (1)
- Dual RAS blockade—unresolved controversy? (2013) (1)
- Renal sympathetic denervation as antihypertensive therapy--a reappraisal of first results. (2013) (1)
- Inhibition of the renin-angiotensin-system in brattleboro rats with hereditary hypothalamic diabetes insipidus (2005) (1)
- VASCULAR ANGIOTENSIN (ANG) FORMATION IN RATS HARBORING THE REN-2 TRANSGENE (1991) (1)
- Increased blood pressure responses to central angiotensin II in spontaneously hypertensive rats (2005) (1)
- What's new in hypertension 2007? (2007) (1)
- [Rational diagnosis of hematuria]. (2008) (1)
- Individuals and Heart Failure in Diabetic and Nondiabetic Albuminuria and Risk of Cardiovascular Events, Death, (2009) (1)
- IMPACT OF MICROVASCULAR DISEASE ON CARDIORENAL OUTCOMES IN TYPE 2 DIABETES: AN ANALYSIS FROM THE LEADER AND SUSTAIN-6 CLINICAL TRIALS (2019) (0)
- Kidney Function Impairment: Do Relevant Differences between Non-Steroidal Anti-Inflammatory Drugs Exist? (1992) (0)
- [Increased sensitivity of vascular muscles in renal and corticosterone hypertension]. (1977) (0)
- [Malignant hypertension]. (1983) (0)
- Cardiovascular Outcomes and Renal Disease (2002) (0)
- Liraglutide and Renal Outcomes in Type 2 Diabetes. (2017) (0)
- [Hypertension as a risk factor for progression of renal failure]. (1992) (0)
- Renal anaemia - CKD 5D (2012) (0)
- R. Bernd Sterzel - obituary (2001) (0)
- Supplemental low-protein diet in chronic renal failure. (1984) (0)
- 1098-79 Renal function predicts outcomes in acute coronary syndromes: Insights from the CURE trial (2004) (0)
- [Renal effects of angiotensin-converting enzyme inhibitors and their therapeutic use in chronic terminal renal failure]. (1988) (0)
- [Conversion enzyme inhibitors in the antihypertensive treatment of patients with renal insufficiency]. (1987) (0)
- Inhibition of the Renin-Angiotensin-System (RAS) in Rats with Hereditary Hypothalamic Diabetes Insipidus (DI) (1978) (0)
- Cardiovascular outcomes and renal disease. Authors' reply (2002) (0)
- 747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial (2022) (0)
- [Cation flux in erythrocytes of patients with essential hypertension]. (1983) (0)
- [Variable action of central and peripheral angiotensin II blockade in genetic hypertension in rats]. (1977) (0)
- Ramipril Global Endpoint Trial / Telmisartan Randomized AssessmeNt Study in ACE withTelmisartan , Ramipril , or Both : The ONgoing Telmisartan Alone and in combination Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving (2010) (0)
- Real-world effects of ACE inhibitors and Angiotensin Receptor Blockers: protocol for an emulation study of the ONTARGET trial using electronic health records (2021) (0)
- Renoprotection with antihypertensive agents (2002) (0)
- E011: The combination of valsartan and benazepril in patients with chronic renal disease (1998) (0)
- [Readjustment of severe hypertension with captopril]. (1983) (0)
- Antihypertensive therapy in patients with type 2 diabetes mellitus: focus on nephropathy. (1999) (0)
- Postersession V: Hypertonie (1984) (0)
- Renal outcomes in the ONTARGET study – Authors' reply (2008) (0)
- Hypertension-Induced Models of Nephrosclerosis in the Rat (1993) (0)
- Pharmacokinetics of muzolimine after acute and chronic dosing in hypertensive patients with mild renal insufficiency. (1985) (0)
- [Modification of genetic hypertension in rats]. (1977) (0)
- [Kidney function in lead burden]. (1986) (0)
- SP55824-MONTH SAFETY OUTCOMES OF BIOSIMILAR EPOETIN ALFA IN THE EUROPEAN MONITOR-CKD5 PHARMACOEPIDEMIOLOGICAL STUDY OF ANAEMIA IN HAEMODIALYSIS (2016) (0)
- In memoriam: A commentary on R. Bernd Sterzel (2001) (0)
- Impact of haemoglobin and erythropoietin dose changes on mortality : a secondary analysis of results from a randomized anaemia management trial (0)
- [Vascular changes in genetic hypertension in rats]. (1977) (0)
- Pharmacokinetic and pharmacodynamic studies of infusions with [Sar1, Val5, Ala8] angiotensin II (saralasin) (2005) (0)
- [What role does the renin-angiotensin system have in the pathogenesis of hypertension?]. (1977) (0)
- Sodium and its interrelationships with other pressor systems in hypertension (1991) (0)
- Kidney Diseases beyond Nephrology What ’ s new in hypertension ? (2006) (0)
- Diabetes mellitus - clinical studies - 2 (2009) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Johannes F. E. Mann?
Johannes F. E. Mann is affiliated with the following schools:
